Trials / Conditions / Urea Cycle Disorders

Urea Cycle Disorders

26 registered clinical trials studyying Urea Cycle Disorders — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Clinical Study of Glycerol Phenylbutyrate in Chinese Patients With Urea Cycle Disorders NCT06904027	Tongji Hospital	—
Enrolling By Invitation	At Home Ammonia Monitoring of Inborn Errors of Ammonia Metabolism NCT06953505	Sequitur Health Corp.	N/A
Recruiting	Ureagenesis Analysis in Healthy Subjects and in Urea Cycle Disorder Patients NCT05671666	University Children's Hospital, Zurich	N/A
Completed	Clinical Food Study to Evaluate the Effect of KB195 on Gut Nitrogen Metabolism in Patients With Urea Cycle Dis NCT03797131	Kaleido Biosciences	N/A
Recruiting	Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders NCT02935283	Children's National Research Institute	—
Completed	PCORI Urea Cycle Disorder Study NCT02740153	Children's National Research Institute	—
Completed	Study to Evaluate the Efficacy of HepaStem in Urea Cycle Disorders Paediatric Patients (HEP002) NCT02489292	Cellaion SA	Phase 2
Completed	Pilot Study: Urea Cycle Disorders Practice Patterns and Outcomes Assessment NCT02311283	University of South Florida	—
Completed	Nitric Oxide Supplementation in Argininosuccinic Aciduria NCT02252770	Baylor College of Medicine	N/A
Completed	Long-term Safety Follow-up Study of Patients Having Received HepaStem (SAF001) NCT02051049	Cellaion SA	—
Completed	Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN) NCT01765283	Cellaion SA	Phase 1 / Phase 2
Terminated	Oxidative Stress, Inflammation and Acute Decompensation in Urea Cycle Disorders NCT01541722	Mark Batshaw	—
Completed	Study in Healthy Subjects, Patients With Urea Cycle Disorders (UCD) and Carriers of UCD Mutations to Evaluate NCT01549015	Cytonet GmbH & Co. KG	N/A
Completed	Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders NCT01347073	Amgen	Phase 3
Terminated	Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders NCT01195753	Cytonet GmbH & Co. KG	Phase 2
Completed	To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs) NCT01257737	Amgen	Phase 4
Completed	Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle NCT00947544	Amgen	Phase 2
Completed	Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD) NCT00947297	Amgen	Phase 3
Completed	Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders NCT00992459	Amgen	Phase 3
Completed	Study to Evaluate 13 C Isotope Ratio Measurement for Urea Cycle Capacity Assessment NCT01002469	Cytonet GmbH & Co. KG	N/A
Completed	Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders NCT00718627	Cytonet GmbH & Co. KG	Phase 2
Completed	Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder NCT00345605	Brendan Lee	Phase 2
Completed	Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders NCT00551200	Amgen	Phase 2
Completed	Pilot Study For Hypothermia Treatment In Hyperammonemic Encephalopathy In Neonates And Very Young Infants NCT01624311	Uta Lichter-Konecki	Phase 2
Completed	A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Con NCT00986895	Amgen	Phase 1
Recruiting	Longitudinal Study of Urea Cycle Disorders NCT00237315	Andrea Gropman	—